NASDAQ : EXAS

Exact Sciences Corporation

$104.91 USD

$0 (0.0%)

Volume
21.56M
Average Volume
2.53M
Market Capitalization
$20.03B
P/E Ratio
-95.69
Dividend Yield
0.00%
Price Target
$105.00
Year High
$104.98
Year Low
$38.81
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.23
Company Overview

NASDAQ

Kevin T. Conroy

Medical - Diagnostics & Research

Healthcare

EXAS

6900

US

USD

https://www.exactsciences.com

608 284 5700

30063P105

0001124140

Liquidity Metrics

1.05

2.23

1.97

1.49

0.00

Sales & Valuation

$3.25B

6.17

8.29

56.13

1.88

Profitability

-$1.1

-$207.95M

-6.40%

-6.28%

-8.51%

-3.55%

P/E Metrics

-95.69

-1.09

-1.09

Analyst Price Target & Rating

$105.00

$135.00

$46.00

N/A

0/5

41 Analysts

-0.09%

Financial Health Scores

2.97

5/9

$788.41M

$5.86B

$3.46B

-$167.24M

Key Metrics (TTM)

$21.59B

6.65

397.39

2.23

-8.51%

-4.05%

-1.04%

1.78%

30 days

Company Executives
Name Title
Aaron Bloomer EVP & CFO
Graham Lidgard Emeritus Chief Science Officer
James Herriott Senior Vice President, General Counsel & Secretary
Nassar Nizami Chief Information Officer
Derek Leckow Vice President of Investor Relations
Jorge A. Garces Chief Science Officer
Brian Baranick Executive Vice President & General Manager of Precision Oncology
Jacob Orville Executive Vice President & GM of Screening
Kevin T. Conroy Chairman of the Board, President & CEO
Sarah Condella Executive Vice President of Human Resources & Service
Poll Results

No votes yet today — be the first to share your view!

About Exact Sciences Corporation (NASDAQ:EXAS) Stock

Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy de ... signed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street

2026-07-16 13:45:22

Abbott Laboratories NYSE: ABT gave the market what it wanted in its Q2 earnings report, affirming that the Exact Sciences acquisition was a good one. The critical takeaways are that comp growth is solid, the Exact Sciences business has traction, and the near-term margin impairment the acquisition brought is less than expected.

Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering

2026-07-03 16:00:00

Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.

Frequently Asked Questions

What is the current Exact Sciences Corporation (EXAS) stock price?

Exact Sciences Corporation(NASDAQ:EXAS) stock price is $104.91 in the last trading session. During the trading session, EXAS stock reached the peak price of $104.98 while $38.81 was the lowest point it dropped to. The percentage change in EXAS stock occurred in the recent session was 0.0% while the dollar amount for the price change in EXAS stock was $0.

EXAS's industry and sector of operation?

The NASDAQ listed EXAS is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of EXAS?

Aaron Bloomer | EVP & CFO
Graham Lidgard | Emeritus Chief Science Officer
James Herriott | Senior Vice President, General Counsel & Secretary
Nassar Nizami | Chief Information Officer
Derek Leckow | Vice President of Investor Relations

How many employees does EXAS have?

Number of EXAS employees currently stands at 6900. EXAS operates from 5505 Endeavor Lane, Madison, WI 53719, US.

Link for EXAS official website?

Official Website of EXAS is: https://www.exactsciences.com

How do I contact EXAS?

EXAS could be contacted at phone #608 284 5700 and can also be accessed through its website. EXAS operates from 5505 Endeavor Lane, Madison, WI 53719, US.

How many shares of EXAS are traded daily?

The average number of EXAS shares traded daily for last 3 months was 2.53M.

What is the market cap of EXAS currently?

The market value of EXAS currently stands at $20.03B with its latest stock price at $104.91